



Diagnosis and Treatment of Allergic Diseases Group


Publications:	36
Impact Factor:	163.046
Q1:	15



Research Activity

Publications

- Agache I, Miller R, Gern JE, Hellings PW, Jutel M, Muraro A, Phipatanakul W, Quirce S, Peden D. Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document. *Allergy*. 2019; 74(3): 449-63. Article. IF: 8,706; D1
- Albers FC, Licskai C, Cháñez P, Bratton DJ, Bradford ES, Yancey SW, Kwon N, Quirce S. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. *Resp Med*. 2019; 159: 105806. Article. IF: 3.095; Q2
- Aparicio, B; Romero, D; París, M; Gómez, T; Ruiz, G; Gutiérrez, FJA; Ortega, D; Palomo, N; Requena, H; Ortega, DAV; Puebla, MJA; Gracia, JAC. Referral criteria for asthma: Consensus document. *J Invest Allerg Clin*. 2019; 29(6): 422-30. Article. IF: 3,488; Q2
- Betschel S, Badiou J, Binkley K, Borici-Mazi R, Hebert J, Kanani A, Keith P, Lacuesta G, Wasserman S, Yang B, Aygoren-Pursun E, Bernstein J, Bork K, Caballero T, Cicardi M, Craig T, Farkas H, Grumach A, Katelaris C, Longhurst H, Riedl M, Zuraw B, Berger M, Boursiquot JN, Boysen H, Castaldo A, Chapdelaine H, Connors L, Fu LS, Goodyear D, Haynes A, Kamra P, Kim H, Lang-Robertson K, Leith E, McCusker C, Moate B, O'Keefe A, Othman I, Poon MC, Ritchie B, St-Pierre C, Stark D, Tsai EL. The international/canadian hereditary angioedema guideline. *Allergy Asthma Clin Immunol*. 2019; 15(1): 72. Review. IF: 2.051; Q3
- Bygum A, Caballero T, Grumach AS, Longhurst HJ, Bouillet L, Aberer W, Zanichelli A, Botha J, Andresen I, Maurer M, Grumach AS, Bygum A, Delaunay CB, Boccon-Gibod I, Bouillet L, Coppere B, Du Thanh A, Dzviga C, Fain O, Goichot B, Gompel A, Guez S, Jeandel PY, Kanny G, Launay D, Maillard H, Martin L, Masseur A, Ollivier Y, Sobel A, Aygoren-Pursun E, Bas M, Bauer M, Bork K, Greve J, Magerl M, Martinez-Saguer I, Maurer M, Strassen U, Papadopoulos-Alataki E, Psarros F, Graff Y, Kivity S, Reshef A, Toubi E, Arcoleo F, Bova M, Cicardi M, Nconi PM, Marone G, Montinaro V, Triggiani M, Zanichelli A, Baeza ML, Caballero T, Cabañas R, Guilarte M, Hernández D, de Larramendi CH, Leonart R, Lobera T, Marqués L, Pedro BSD, Bjorkander J, Bethune C, Garcez T, Longhurst HJ. Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey. *Clin Transl Allergy*. 2019; 9: 37. Article. IF: 5.129; Q1
- Campo P, Campos GS, Aparicio MB, Jorge AM, Expósito HMG, Quirce S, Dávila I. Severe asthma phenotypes in patients controlled with omalizumab: A real-world study. *Resp Med*. 2019; 159: 105804. Article. IF: 3.095; Q2
- Contreras-Porta J, Vilchez-Sánchez F, Loli-Ausejo D, Fiandar A, Domínguez-Ortega J. When education in asthma is crucial. About a case. *Rev Alerg Mex*. 2019; 66(4): 493-8. Article. Not Indexed
- Craig T, Lumry W, Cicardi M, Zuraw B, Bernstein JA, Anderson J, Jacobs J, Riedl MA, Manning ME, Bannerji A, Gower RG, Caballero T, Farkas H, Feuersen-ger H, Jacobs I, Machnig T, Longhurst H. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. *J Allergy Clin Immunol Pract*. 2019; 7(6): 2035-8. Letter. IF: 7.574; Q1
- Craig T, Zuraw B, Longhurst H, Cicardi M, Bork K, Grattan C, Katelaris C, Sussman G, Keith PK, Yang W, Hebert J, Hanzlikova J, Staubach-Renz P, Martínez-Saguer I, Magerl M, Aygoren-Pursun E, Farkas H, Reshef A, Kivity S, Neri S, Crisan I, Caballero T, Baeza ML, Hernández MD, Li H, Lumry W, Bernstein JA, Hussain I, Anderson J, Schwartz LB, Jacobs J, Manning M, Levy D, Riedl M, Christiansen S, Feuersenger H, Pragst I, Mycroft S, Pawaskar D, Jacobs I, Zuraw BL, Cicardi M, Craig T, Longhurst H, Grattan C, Grattan C, Bork K, Kreuz W, Jacobs I, Pragst I, Herget S, Dalton S, Clement C, Mycroft S, Pawaskar D, Zhang Y, Machnig T, Waldhauser H, Feuersenger H, Lawo JP, Lang D, Hoernlein S, Miltenberger M, Foeller K, Ellis F, Wood D, Walsh M, Qu QL, Mueller-Stark K, Feussner A, Kalina U, Ma X,



Rigsby S, Scheffler E, Fischer JF, Kolb C, Katelaris CH, Frankum B, Keat K, Philip B, Lee JA, Urriola N, Lee MW, Sussman GL, Levi G, Gould W, Keith PK, Ferrrie P, Rosenberg E, Wasserman S, Yang W, O'Quinn J, Hebert J, Gagnon R, Hanzlikova J, Vachova M, Stauerbach-Renz P,

Weber A, Zimmer S, Gilfert T, Lang B, Martínez-Saguer I, Escuriola-Ettingshausen C, Magerl M, Maurer M, Metz M, Schoepke N, Altrichter S, Hawro T, Schwabe D, Graff J, Behrens F, Kohm M, Andarawewa S, Farkas H, Temesszentandrási G, Kohalmi VK, Reshef A, Kidon M, Kivity S, Kadar L, Benor S, Cicardi M, Bonanni E, Wu M, Zanichelli A, Mansi M, Neri S, Rizzotto A, Giardino F, Fidone F, Crisan I, Varga M, Iftene M, Badiu-Tisa ID, Caballero T, Cabañas R, Pedrosa M, Rivero-Paparoni D, Gómez-Traseira C, Alvez A, Phillips E, Baeza ML, Prieto A, Zubeldia J, Hernández MD, Ibáñez E, Almero R, Longhurst H, Buckland M, Grigoriadou S, Manson A, Yeatman N, Laffan J, Nasr I, Ghurye R, Rehman T, Craig T, Schaeffer C, Ghaffari G, Kelbel T, Reddy V, Buyantseva L, Mende C, Jose J, Novchicht T, Li HH, Scarupa M, Economides A, White M, Kaliner M, Ward C, Shaikh S, Johnson T, Kosh L, Dauphin P, Baker J, Persons S, Newman A, Noonan MJ, Lumry WR, Poarch KP, Tucker J, Aguilar D, Noth D, Bernstein J, Bernstein D, Evans S, Crawford M, McGuckin SD, McCollum JR, Bradley B, Wagner C, Cartwright A, Bonner J, Anderson J, Soong W, Sikora M, Lemke M, Luthin P, Youngblood B, DeBerry E, Schwartz LB, Gilbert E, Zhao W, Ward B, Álvarez A, Kumar S, Akl E, Jacobs J, Curl J, Silva K, Mostofi T, Schultz N, Manning ME, Davis A, Nelson J, Levy DS, Riedl M, Zuraw B, Christiansen SC. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. *J Allergy Clin Immunol Pract.* 2019; 7(6): 1793-802. Article. IF: 7.574; Q1

- Dávila I, Quirce S, Olaguibel JM. Selection of biologics in severe asthma: A multifaceted algorithm. *J Invest Allerg Clin.* 2019; 29(4): 325-8. Editorial Material. IF: 3.488; Q2
- de Llano LAP, Cosío BG, Domingo C, Urrutia I, Bolea I, Valero A, Costa LME, Quirce S, Barranco P, Malanda NM, Andres LP, Álvarez-Gutiérrez FJ. Efficacy and safety of reslizumab in patients with severe asthma with inadequate response to omalizumab: A multicenter, open-label pilot study. *J Allergy Clin Immunol Pract.* 2019; 7(7): 2277-83. Article. IF: 7.574; Q1
- García-Río, F; Álvarez-Puebla, MJ; Esteban-Gorgojo, I; Barranco, P; Olaguibel, JM. Obesity and asthma: Key clinical questions. *J Invest Allerg Clin.* 2019; 29(4): 262-71. Review. IF: 3.488; Q2
- González D, Benítez M, Quirce S. Benralizumab: A new approach for the treatment of severe eosinophilic asthma. *J Invest Allerg Clin.* 2019; 29(2): 84-93. Review. IF: 3.488; Q2
- González-Cavero L, Gómez-Traseira C, Fiandor A, Entrala A, Quirce S. Desensitization to filgrastim in a 2-year-old girl with a vaginal endodermal sinus tumor. *J Invest Allerg Clin.* 2019; 29(4): 329-30. Editorial Material. IF: 3.488; Q2
- Grumach AS, Longhurst HJ, Aberer W, Bouillet L, Caballero T, Bygum A, Zanichelli A, Botha J, Andresen I, Maurer M. Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey findings. *J Allergy Clin Immunol Pract.* 2019; 7(3): 1078-80. Letter. IF: 7.574; Q1
- Hellings PW, Seys SF, Marien G, Agache I, Canonica W, Gevaert P, Hahtela T, Klimek L, Mullol J, Pfaar O, Scadding G, Scadding G, Valiulis A, Bousquet J, Pugin B, Al-Muhandis N, Allatt S, Almeyda R, Armand P, Markovic MA, Bajoriuniene I, Banik AN, Barbar-Craig H, Barraclough J, Bedford C, Bedrock A, Beel M, Parra DB, Bradatan E, Bras M, Brehmer D, Brinkman D, Suárez MC, Llatas MC, Chipev P, Cooper A, Corbett D, Cox C, Cox T, Decsi M, Dantis C, Davies D, de la Hoz B, Culla MTD, Dworan-Timmler A, Edlinger S, El Rakhawy M, El-Shanawany T, Halawa WE, Fauquert JL, Folliard A, Frankland



- K, Gardner J, Gaskin J, Guiddur T, Hanks KA, Hanna B, Heinz B, Hettige R, Horisberger A, Hosotte M, Howe D, Hox V, Ifeacho S, Jain A, Jaramillo M, Morales JMJ, Kale S, Kamper Y, Kansal G, Kapustova L, Karamchandani D, Keh S, Kerr U, Khan M, Kosnik M, Kolar M, Koos B, Kostov K, Kraxner H, Kvedaric V, Lawton S, Lefevre S, Lentari E, Lindenberger M, Litschel R, Lozar M, Lokovska M, Luckhardt C, Lukits J, Marchuk O, Marlair C, Martens K, Mateo JM, Mc Donald S, Guardiola MIM, Mohammad M, Cosme JM, Morgans M, Morris A, Mustakov T, Na deem S, Nagy A, Nemecek R, Nemeth B, Neukirch C, Odeh I, Patiar S, Pavic M, Peglion A, Pentland J, de Corgnal ACP, Petrovicova O, Piccininni K, Piont V, Popov T, Popovics E, Portejoie F, Quirce S, Ram B, Ramonaite A, Juratli AR, Rico P, Ritterhoff C, Robertson A, Fernandes RR, Runge S, Ryan D, Gutiérrez RS, Schatteman I, Scheire S, Schuhmacher-Koval A, Pliego ES, Shukla R, Siau D, Siemers M, Sitkauskienė B, Slomskis T, Kosak TS, Speleman K, Spindler T, Straetmans J, Striupaitiene D, Sunk W, Tadikonda R, Tariq M, Terporten B, Toma S, Tor M, Tsirevelou P, Urban M, Urbancic J, van der Putten L, Vasiliu VC, Vesilyk N, Vink AS, Vriess-Uss E, Vu K, Yaremchuk S, Yong P, Zahoor T, Zidarn M. ARIA masterclass 2018: From guidelines to real-life implementation. *Rhinology*. 2019; 57(5): 392-9. Article. IF: 3.019; D1
- Jeebhay MF, Moscato G, Bang BE, Folletti I, Lipska-Ojrzanowska A, Lopata AL, Pala G, Quirce S, Raulf M, Sastre J, Swoboda I, Walusiak-Skorupa J, Siracusa A. Food processing and occupational respiratory allergy- An EAACI position paper. *Allergy*. 2019; 74(10): 1852-71. Article. IF: 8.706; D1
 - Llungor M, Barranco P, Amaya ED, Domínguez-Ortega J, López-Carrasco V, Comán I, Quirce S. Relationship between upper airway diseases, exhaled nitric oxide, and bronchial hyperresponsiveness to methacholine. *J Asthma*. 2019; 56(1): 53-60. Article. IF: 1.899; Q3
 - López-Lera A, Garrido S, Nozal P, Skatum L, Bygum A, Caballero T, Trascasa ML. Serum complexes between C1INH and C1INH autoantibodies for the diagnosis of acquired angioedema. *Clin Exp Immunol*. 2019; 198(3): 341-50. Article. IF: 3.532; Q2
 - Marqués-Mejías MA, Cabañas R, Ramírez E, Domínguez-Ortega J, Fiandor A, Trigo E, Quirce S, Bellón T. Lymphocyte transformation test (LTT) in allergy to benzimidazole: A promising approach. *Front Pharmacol*. 2019; 10: 469. Article. IF: 4.225; Q1
 - Marqués-Mejías MA, Tomás-Pérez W, Hernández I, López I, Quirce S. Asthma exacerbations in the pediatric emergency department at a tertiary hospital: Association with environmental factors. *J Invest Allerg Clin*. 2019; 29(5): 365-70. Article. IF: 3.488; Q2
 - Monge-Ortega OP, Domínguez-Ortega J, González-Muñoz M, Cabañas R, Lluch-Bernal MM, Fiandor A, Bravo-Gallego LY, Quirce S. Delayed allergic reaction to furosemide with a positive lymphocyte transformation test. *Rev Alerg Mex*. 2019; 66(2): 254-6. Article. Not Indexed
 - Moreno CM, Quirce S, Huerta A, Uria E, Cuesta M. Economic impact of severe asthma in Spain: multicentre observational longitudinal study. *J Asthma*. 2019; 56(8): 861-71. Article. IF: 1.899; Q3
 - Movsisyan M, Fiandor A, González-Muñoz M, Quirce S, Bellón T, Hakobyan A, Marqués-Mejías MA, Domínguez-Ortega J, Cabañas R. The lymphocyte transformation test is useful in the diagnosis of fixed drug eruption induced by etoricoxib. *J Invest Allerg Clin*. 2019; 29(4): 307-9. Editorial Material. IF: 3.488; Q2
 - Pérez-Tavárez R, Carrera M, Pedrosa M, Quirce S, Rodríguez-Pérez R, Gasset M. Reconstruction of fish allergenicity from the content and structural traits of the component beta-parvalbumin isoforms. *Sci Rep-Uk*. 2019; 9: 16298. Article. IF: 3.998; Q1
 - Quirce S, Sastre J. Occupational asthma: clinical phenotypes, biomarkers, and management. *Curr Opin Pulm Med*. 2019; 25(1): 59-63. Review. IF: 2.63; Q3
 - Rodrigo-Muñoz JM, Canas JA, Sastre B, Rego N, Greif G, Rial M, Minguez P, Mahillo-Fernández I, Fernández-Nieto M, Mora I, Barranco P, Quirce S, Sastre J, del Pozo V. Asthma diagnosis using integrated analysis of eosinophil microRNAs. *Allergy*. 2019; 74(3): 507-17. Article. IF: 8.706; D1
 - Rodrigo-Muñoz JM, Rial MJ, Sastre B, Cañas JA, Mahillo-Fernández I, Quirce S, Sastre J, Cosío BG, del Pozo V. Circulating miRNAs as diagnostic tool for discrimination of respiratory disease: Asthma, asthma-chronic obstructive pulmonary disease [COPD] overlap and COPD. *Allergy*. 2019; 74(12): 2491-4. Article. IF: 8.706; D1
 - Sánchez VF, Bernal ML, Muñoz MG, Mejías MAM, Quirce S, Moreno RC. Usefulness of the basophil activation test in the diagnosis of hypersensitivity to amiodarone. *J Invest Allerg Clin*. 2019; 29(5): 378-9. Editorial Material. IF: 3.488; Q2
 - Sánchez-Jareno M, Bananco P, Romero D, Domínguez-Ortega J, Quirce S. Severe eosinophilic allergic asthma responsive to mepolizumab after failure of 2 consecutive biologics. *J Invest Allerg Clin*. 2019; 29(1): 79-81. Article. IF: 3.488; Q2
 - Sánchez-Jareno M, Barranco P, Vilchez MAP, Valbuena T, Lluch M, Domínguez-Ortega J, López-Carrasco V, Quirces S. Changes in fractional exhaled nitric oxide levels after bronchial challenge with aspirin in patients with aspirin-induced asthma. *J Invest Allerg Clin*. 2019; 29(2): 137-9. Article. IF: 3.488; Q2
 - Seys SF, Quirce S, Agache I, Akdis CA, Alvaro-Lozano M, Antolin-Amerigo D, Bjermer L, Bobolea I, Bonini M, Bossios A, Brinkman P, Bush A, Calderon M, Canonica W, Chané P, Couto M, Dávila I, del Giacco S, del Pozo V, Erjefalt JS, Gevaert P, Hagedoorn P, Heaney LG, Heffler E, Hellings PW, Jutel M, Kalayci O, Kurowski MM, Loukides S, Nair P, Palomares O, Polverino E, Sánchez-García S, Sastre J, Schwarze J, Spanevello A, Ulrik CS, Usmani O, Van den Berge M, Vasakova M, Vijverberg S, Diamant Z. Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018. *Allergy*. 2019; 74(11): 2244-8. Letter. IF: 8.706; D1
 - Tomás-Pérez M, Hernández-Martín I, Fernández de Alba-Parcel I, Pagola MJ, Carretero P, Domínguez-Ortega J, Lluch-Bernal MM, Caballero ML, Quirce S. Allergy to vegetables belonging to the Solanaceae family. *Rev Alerg Mex*. 2019; 66(3): 322-8. Article. Not Indexed
 - Valero A, Olaguibel J, Delgado J, Plaza V, Álvarez F, Molina J, Mascaros E, Quirce S. Dilemmas and new paradigms in asthma management. *J Invest Allerg Clin*. 2019; 29(1): 15-23. Review. IF: 3.488; Q2
 - Vandenplas O, Godet J, Hurdubaea L, Riffart C, Suojalehto H, Walusiak-Skorupa J, Muñoz X, Sastre J, Klusackova P, Moore V, Mergert R, Talini D, Kirkeleit J, Mason P, Folletti I, Cullinan P, Moscató G, Quirce S, Hoyle J, Sherson D, Kauppi P, Preisser A, Meyer N, de Blay F, Holttta P, Harth V, Maestrelli P, Pignatti P, Paggiaro P, dell'Orno M, Svanes C, Wiszniewska M, Romero-Mesones C, Fernández-Nieto M, Sánchez-Jareno M, Cannon J, Burge S. Severe occupational asthma: Insights from a multicenter European cohort. *J Allergy Clin Immunol Pract*. 2019; 7(7): 2309-2318. Article. IF: 7.574; Q1
 - Vandenplas O, Godet J, Hurdubaea L, Riffart C, Suojalehto H, Wiszniewska M, Muñoz X, Sastre J, Klusackova P, Moore V, Mergert R, Talini D, Svanes C, Mason P, dell'Orno M, Cullinan P, Moscató G, Quirce S, Hoyle J, Sherson DL, Kauppi P, Preisser A, Meyer N, de Blay F. Are high- and low-molecular-weight sensitizing agents associated with different clinical phenotypes of occupational asthma? *Allergy*. 2019; 74(2): 261-72. Article. IF: 8.706; D1

Research projects

Caballero Molina MT. Development and trans-cultural validation of an international specific questionnaire (IHAE-QoL) For assessment of Health related quality of life in adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE) and quality of life. Hereditary Angio-Edema Inc. 2009-Ongoing.

Management centre: FIBHULP

Caballero Molina MT. Nuevos biomarcadores en enfermedades mediadas por el sistema del complemento (PI15/00255). ISCIII. 2016-2020.

Management centre: FIBHULP

Domínguez Ortega FJ. Asesoramiento para el diseño del estudio clínico "ensayo clínico prospectivo multicéntrico aleatorizado de doble simulación controlado con placebo de búsqueda de la dosis más eficaz para el tratamiento de rinitis/rinoconjuntivitis por alergia. Immunotek. 2015-Ongoing.

Management centre: FIBHULP

Quirce Gancedo S. E-PHOCAS (PHenotyping of Occupational Asthma). EAACI (European



Academy of Allergy and Clinical Immunology). 2016-2020.

Management centre: University Hospital of Strasbourg

Quirce Gancedo S. II Jornadas científicas sobre conocimientos básicos en patología alérgica para un médico residente e investigadores del Hospital Universitario La Paz. Glaxosmithkline S.A. 2018-Ongoing.

Management centre: FIBHULP

Quirce Gancedo S. New findings in asthma, allergy and atopic dermatitis. Omnix Pharma S.L. 2018-Ongoing.

Management centre: FIBHULP

Quirce Gancedo S. Programa de la unidad multidisciplinaria de asma grave de La Paz: de la investigación a la práctica clínica. AstraZeneca Farmaceutica Spain S.A. 2019-Ongoing.

Management centre: FIBHULP

Quirce Gancedo S. Relación entre asma y obesidad en la población española mayor o igual a 18 años. Novartis Farmaceutica S.A. 2009-Ongoing.

Management centre: FIBHULP

Quirce Gancedo S. Sesiones en investigación del diagnóstico molecular como herramienta de identificación de perfiles de respuesta en pacientes con enfermedad respiratoria alérgica y alergia a alimentos. Thermo Fisher Diagnostics S.L.U. 2017-Ongoing.

Management centre: FIBHULP

Quirce Gancedo S. Towards precision medicine in the study of risk factors and triggers of asthma [PREMEDAS]. CIBERES. 2017-2019.

Management centre: Hospital Valle Hebrón

Rodríguez Pérez MR. Contrato Miguel Servet Estabilizado I2 (CPII13/00022). CM. 2014-2020.

Management centre: FIBHULP

Rodríguez Pérez MR. Desarrollo de un programa formativo de formación en investigación en centros de trabajo. Colegio Valle del Miro. 2016-Ongoing.

Management centre: FIBHULP

Rodríguez Pérez MR. Evaluación de la capacidad alérgica de productos alimentarios mediante test de activación de basófilos y sensibilización cutánea con alimentos. Angulas Aguinaga S.A.U. 2018-Ongoing.

Management centre: FIBHULP

Cibers and Retics

Caballero Molina MT. Networked Biomedical Research Center for Rare Diseases. [CIBERer]. ISCIII. [31/12/2021].

Management centre: FIBHULP

Clinical trials

Caballero Molina MT. BCX7353-302: un estudio fase 3, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de dos dosis diferentes de BCX7353 como tratamiento oral para la prevención de ataques en pacientes con angioedema hereditario. Type: EECC, phase III.

HULP code: ANEXO-I 4984.

Sponsored's protocol code: BCX7353-302.

Sponsored by: Biocryst Pharmaceuticals, Inc.

Signed date: 24/01/2019

Caballero Molina MT. Estudio de extensión multicéntrico y abierto para evaluar la seguridad y tolerabilidad a largo plazo de LOU064 en pacientes elegibles con urticaria crónica espontánea que hayan participado en CLOU064A2201. Type: EECC, phase II.

HULP code: 5353.

Sponsored's protocol code: CLOU064A2201E1.

Sponsored by: Novartis Farmacéutica, S.A.

Signed date: 10/12/2019

Caballero Molina MT. Estudio fase 2B, de búsqueda de dosis, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para investigar la eficacia, seguridad y tolerabilidad de LOU064 en pacientes adultos con urticaria crónica espontánea inadecuadamente controlados con antihistamínicos H1. Type: EECC, phase II.

HULP code: 5166.

Sponsored's protocol code: CLOU064A2201.

Sponsored by: Novartis Farmacéutica, S.A.

Signed date: 26/02/2019

Dominguez Ortega FJ. Determinación de diferentes perfiles de sensibilización alérgica mediada por IGE en pacientes de diferentes regiones de la geografía española a través del análisis de sueros. Type: ESTUDIOS, phase NO-EPA.

HULP code: pi-3573.

Sponsored's protocol code: LET-IGE-2018-01.

Sponsored by: Laboratorios Leti, S.L.

Signed date: 14/05/2019

Luna Porta JA. Ensayo multicéntrico de fase II, doble ciego, aleatorizado, de grupos paralelos y controlado por placebo, para investigar el efecto del antagonista PBF-680 de receptor A1 de Adenosina sobre el volumen espiratorio forzado en 1 segundo (FEV1) en sujetos con asma atópica persistente leve a moderada. Type: EECC, phase II.

HULP code: 5293.

Sponsored's protocol code: PBF-680CT-05.

Sponsored by: Palobiofarma, S.L.

Signed date: 29/05/2019

Pedrosa Delgado M. Estudio de fase 3, abierto y multicéntrico para evaluar la seguridad, la farmacocinética y la farmacodinamia de Lanadelumab para la prevención de las cri-

sis agudas de angioedema hereditario (AEH) en pacientes pediátricos de 2 a menos de 12 años. Type: EECC, phase III.

HULP code: 5390.

Sponsored's protocol code: SHP643-301.

Sponsored by: Dyax Corp.

Signed date: 20/08/2019

Patents and trademarks

Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

HAE-QoL
HEREDITARY ANGIOEDEMA QUALITY OF LIFE

Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EP16382413.9 [Publication Number pending]; 2016 September 06.

del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIISFJD, Centro de Investigación Biomédica en Red [CIBER], FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees. In vitro method for identifying severity levels in bronchial asthma patients. P201730739; 2017 May 29.